Ratings by RBC Capital (Lisa Walter)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/27/2026 | Viridian Therapeutic | VRDN | Maintain | (N/A) |
|
Details | ||
| 2/27/2026 | Rhythm Pharmaceuticals | RYTM | Maintain | (N/A) |
|
Details | ||
| 2/26/2026 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/25/2026 | Apellis Pharmaceuticals | APLS | Maintain | (N/A) |
|
Details | ||
| 2/18/2026 | Rhythm Pharmaceuticals | RYTM | New Coverage | Outperform (N/A) |
102.53 (93.52) |
-8.79% | Details | |
| 2/5/2026 | Ocular Therapeutix | OCUL | Maintain | Outperform (N/A) |
|
Details | ||
| 2/5/2026 | EyePoint Inc. | EYPT | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2026 | 4D Molecular Therapeutics | FDMT | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2026 | EyePoint Inc. | EYPT | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2025 | Ocular Therapeutix | OCUL | Maintain | Outperform (N/A) |
|
Details | ||
| 11/14/2025 | MeiraGTx Holdings plc | MGTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2025 | 4D Molecular Therapeutics | FDMT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2025 | EyePoint Pharmaceuticals, Inc. | EYPT | Maintain | (N/A) |
|
Details | ||
| 11/6/2025 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/5/2025 | Ocular Therapeutix | OCUL | Maintain | Outperform (N/A) |
|
Details | ||
| 10/30/2025 | United Therapeutics Corp. | UTHR | Maintain | (N/A) |
|
Details | ||
| 10/30/2025 | United Therapeutics Corp. | UTHR | Maintain | (N/A) |
|
Details | ||
| 10/28/2025 | Adverum Biotechnologies | ADVM | Maintain | Sector Perform (N/A) |
|
Details | ||
| 10/21/2025 | 4D Molecular Therapeutics | FDMT | Maintain | Outperform (N/A) |
|
Details | ||
| 10/20/2025 | Apellis Pharmaceuticals | APLS | Maintain | Sector Perform (N/A) |
|
Details | ||
| 9/26/2025 | United Therapeutics Corp. | UTHR | New Coverage | Outperform (N/A) |
438.75 (478.16) |
8.98% | Details | |
| 8/7/2025 | Viridian Therapeutic | VRDN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/1/2025 | Apellis Pharmaceuticals | APLS | Maintain | Sector Perform (N/A) |
|
Details | ||
| 7/7/2025 | Apellis Pharmaceuticals | APLS | Maintain | Sector Perform (N/A) |
|
Details | ||
| 6/17/2025 | EyePoint Pharmaceuticals, Inc. | EYPT | New Coverage | Outperform (N/A) |
8.90 (15.75) |
76.97% | Details | |
| 5/9/2025 | 4D Molecular Therapeutics | FDMT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/8/2025 | Apellis Pharmaceuticals | APLS | Maintain | Sector Perform (N/A) |
|
Details | ||
| 4/21/2025 | Apellis Pharmaceuticals | APLS | Maintain | Sector Perform (N/A) |
|
Details | ||
| 4/16/2025 | Adverum Biotechnologies | ADVM | Maintain | Sector Perform (N/A) |
|
Details | ||
| 4/3/2025 | Apellis Pharmaceuticals | APLS | Maintain | Sector Perform (N/A) |
|
Details | ||
| 3/17/2025 | MeiraGTx Holdings plc | MGTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2025 | Apellis Pharmaceuticals | APLS | Maintain | Sector Perform (N/A) |
|
Details | ||
| 3/3/2025 | 4D Molecular Therapeutics | FDMT | Maintain | Outperform (N/A) |
|
Details | ||
| 1/7/2025 | Apellis Pharmaceuticals | APLS | Maintain | Sector Perform (N/A) |
|
Details | ||
| 10/25/2024 | Apellis Pharmaceuticals | APLS | New Coverage | Sector Perform (N/A) |
27.58 (20.07) |
-27.23% | Details | |
| 7/22/2024 | 4D Molecular Therapeutics | FDMT | Maintain | Outperform (N/A) |
|
Details | ||
| 6/26/2024 | 4D Molecular Therapeutics | FDMT | Maintain | Outperform (N/A) |
|
Details | ||
| 4/15/2024 | 4D Molecular Therapeutics | FDMT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/5/2024 | 4D Molecular Therapeutics | FDMT | Maintain | Outperform (N/A) |
|
Details |
